We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GMP Ancillary Materials for Cell and Gene Therapy Manufacturing

GMP Ancillary Materials for Cell and Gene Therapy Manufacturing content piece image

Ancillary materials (AMs), also called raw materials in Europe, are components, reagents, and materials used in the manufacturing of cell, gene, and tissue-engineered (CGT) therapies but are not intended to be present in the final product formulation. AMs include, but are not limited to, cell culture reagents and additives (e.g. transfection reagents and antibiotics), cryopreservation agents, and disposables such as plasticware and bioprocessing bags. While ancillary materials are not intended to be detectable in the final therapeutic, their presence in the manufacturing process may affect the final drug's safety, efficacy, stability and consistency. Therefore, it is critical for CGT therapy manufacturers to carefully define the selection criteria and subsequent qualification program for AMs.

Watch now to learn about:

  • What is a GMP Ancillary material and the associated regulatory challenges?
  • Key raw material considerations when choosing suppliers 
  • Importance and impact of raw material selection for commercial manufacture 
Kasey Kime
Kasey Kime
Senior Manager, Regulatory Affairs
Eric Roos
Eric Roos
Strategic Alliance Manager